^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    TYK2 (Tyrosine Kinase 2)

    i
    Other names: TYK2, Tyrosine Kinase 2, Non-Receptor Tyrosine-Protein Kinase TYK2, IMD35, JTK1
    3d
    HDAC3 inhibition as a therapeutic strategy in T-cell acute lymphoblastic leukemia via the TYK2-STAT1-BCL2 signaling pathway. (PubMed, Front Immunol)
    HDAC3 was found to associate with TYK2 and contributed to activation of the TYK2-STAT1-BCL2 signaling pathway in T-ALL cells. Our results highlight the effectiveness of the combination of chidamide and chemotherapy in the treatment of T-ALL patients and suggest that HDAC3 can act as a potential novel therapeutic target to inhibit the TYK2-STAT1-BCL2 signaling pathway in T-ALL.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • HDAC2 (Histone deacetylase 2) • TYK2 (Tyrosine Kinase 2) • HDAC10 (Histone Deacetylase 10) • HDAC3 (Histone Deacetylase 3)
    |
    Epidaza (chidamide)
    17d
    Analysis of the molecular mechanism underlying di(2-ethylhexyl) phthalate-induced bladder carcinogenesis via network toxicology and molecular docking approaches: An observational study. (PubMed, Medicine (Baltimore))
    DEHP may promote the development of BLCA by interacting with key proteins and signaling pathways. This study provides a theoretical basis for understanding the molecular mechanisms of DEHP-induced BLCA and offers references for future prevention and treatment strategies.
    Observational data • Journal
    |
    BCL2 (B-cell CLL/lymphoma 2) • IL6 (Interleukin 6) • CDK2 (Cyclin-dependent kinase 2) • TYK2 (Tyrosine Kinase 2) • CCNB2 (Cyclin B2) • CDK1 (Cyclin-dependent kinase 1) • CCNB1 (Cyclin B1)
    19d
    ERBB2 I655V mutation correlates with efficacy of immunotherapy in gallbladder cancer. (PubMed, World J Surg Oncol)
    The ERBB2 I655V mutation may be associated with improved treatment response to immunotherapy in gallbladder cancer.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • TYK2 (Tyrosine Kinase 2)
    |
    PD-L1 expression • HER-2 overexpression • HER-2 mutation
    |
    Focus V (anlotinib) • AiRuiKa (camrelizumab)
    23d
    A Real-World Study of Precision Treatment for Advanced Cholangiocarcinoma Based on Molecular Subtyping (ChiCTR2500111407)
    P=N/A, N=55, Not yet recruiting, Fuzhou University Affiliated Provincial Hospital; Fuzhou University Affiliated Provincial Hospital
    New trial
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MET (MET proto-oncogene, receptor tyrosine kinase) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MSI (Microsatellite instability) • RET (Ret Proto-Oncogene) • FGFR2 (Fibroblast growth factor receptor 2) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • NRG1 (Neuregulin 1) • VEGFA (Vascular endothelial growth factor A) • RNF43 (Ring Finger Protein 43) • TYK2 (Tyrosine Kinase 2) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    BRAF V600E • KRAS mutation • EGFR mutation • MSI-H/dMMR • HER-2 overexpression • HER-2 amplification • PIK3CA mutation • BRAF V600 • MET amplification • RET fusion • FGFR2 mutation • PALB2 mutation • FGFR2 fusion • MET mutation • IDH mutation + BRAF V600E • IDH mutation + NTRK fusion
    28d
    Case Report: diffuse entire gastrointestinal tract involvement of ALK-positive anaplastic large cell lymphoma harboring JAK-STAT pathway mutations in an adolescent with leukemoid reaction. (PubMed, Front Oncol)
    In further studies, RNA sequencing confirmed the presence of NPM1::ALK gene fusion in this case; whole-exome sequencing (WES) detected somatic mutations in multiple genes of the JAK-STAT pathway (including JAK1, PTPN6, MTOR, and TYK2). It is noteworthy that such genetic alterations are more commonly observed in ALK-negative anaplastic large cell lymphoma (ALK-ALCL) but are less commonly reported in ALK+ALCL.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • NPM1 (Nucleophosmin 1) • TNFRSF8 (TNF Receptor Superfamily Member 8) • JAK1 (Janus Kinase 1) • TYK2 (Tyrosine Kinase 2)
    |
    ALK positive • ALK fusion • TNFRSF8 positive • TNFRSF8 expression • ALK translocation • ALK negative
    1m
    Selective TYK2 Inhibition, Prenatal Cell Diagnostics, and Biomarker-Guided Immunotherapy: Expanding Precision Medicine. (PubMed, ACS Med Chem Lett)
    Brain-penetrant TYK2 inhibitors target autoimmune and neuroinflammatory disease, fetal cell diagnostics improve prenatal screening, and biomarker signatures refine checkpoint immunotherapy. Together, these advances highlight how molecular, cellular, and patient-level selectivity drives therapeutic precision across neurology, oncology, immunology, and reproductive health, reshaping diagnostics and treatment strategies from early development through complex disease.
    Journal • IO biomarker
    |
    TYK2 (Tyrosine Kinase 2)
    1m
    Impact of rare JAK/STAT germline mutations on vaccination-induced innate immune responses in a Tyrolian population. (PubMed, Int J Biol Sci)
    We also identified co-occurring variants in TYK2 and other modulators of interferon signaling that possibly modify the impact of JAK and STAT variants in the innate immune response. Our results demonstrate that the vaccine-induced innate immune transcriptomic response can be used for an in vivo functional assessment of mutations controlling key genetic pathways in the innate immune response.
    Journal
    |
    TYK2 (Tyrosine Kinase 2)
    2ms
    Daucosterol Inhibits Glycolysis and Malignant Progression of Lung Adenocarcinoma by Targeting ERBB2-mediated PI3K/AKT Pathway Based on Network Pharmacology. (PubMed, J Biochem Mol Toxicol)
    DS exerts anti-tumor effects in LUAD by directly regulating ERBB2 expression, inhibiting PI3K/AKT signaling, and disrupting glycolysis. These findings support DS as a promising therapeutic candidate for LUAD.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • LDHA (Lactate dehydrogenase A) • TYK2 (Tyrosine Kinase 2) • HK2 (Hexokinase 2)
    |
    HER-2 overexpression • HER-2 expression
    2ms
    NTRK2 promotes malignant progression and paclitaxel resistance of lung adenocarcinoma through targeting MYC/ABCF1 axis. (PubMed, Transl Oncol)
    Collectively, our findings identify NTRK2 as a critical oncogenic driver that confers chemoresistance by activating the NTRK2/MYC/ABCF1 signaling axis. This study provides new mechanistic insights into the regulation of paclitaxel resistance in LUAD and highlights NTRK2 and its downstream effectors as promising therapeutic targets for overcoming chemoresistance.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • TYK2 (Tyrosine Kinase 2) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    paclitaxel
    2ms
    Editor's Highlights-February 2026. (PubMed, Int J Dermatol)
    Key topics include vaccination strategies in patients receiving Janus kinase inhibitors, ocular complications associated with atopic dermatitis, malignancy considerations in biologic-treated psoriasis, long-term efficacy and safety of selective tyrosine kinase 2 (TYK2) inhibition, and dose optimization of biologic therapy in hidradenitis suppurativa. Together, these contributions highlight a shift toward personalized, risk-aware management strategies that balance sustained efficacy with long-term safety in chronic inflammatory dermatoses.
    Journal
    |
    TYK2 (Tyrosine Kinase 2)
    2ms
    Bioinformatics analysis reveals C5AR1's impact on thyroid cancer development via immune infiltration. (PubMed, Sci Rep)
    These findings indicate statistical associations rather than causal mechanisms, highlighting the need for further experimental validation. The results provide a foundation for targeted immunotherapy strategies in THCA treatment.
    Journal • IO biomarker
    |
    TYK2 (Tyrosine Kinase 2) • NRP1 (Neuropilin 1)
    2ms
    Propofol suppresses esophageal cancer tumorigenesis by modulating circular RNA protein tyrosine kinase 2/microRNA-134-5p/poly ADP-ribose polymerase 9 axis. (PubMed, J Biochem Mol Toxicol)
    Propofol exerted an antitumor role in EC advancement at least partly through the circ-PTK2/miR-134-5p/PARP9 axis, providing new insight into the involvement of circRNAs in propofol-mediated effect on EC progression. This study also provides evidence that circ-PTK2 could be developed as a potential therapeutic target for EC patients.
    Journal • PARP Biomarker
    |
    PARP1 (Poly(ADP-Ribose) Polymerase 1) • TYK2 (Tyrosine Kinase 2) • PTK2 (Protein Tyrosine Kinase 2) • MIR134 (MicroRNA 134)